Experimental vaccine fights sarcoma with Patient's own immune cells

NCT ID NCT07648069

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized cancer vaccine (SarcVac) combined with immune-boosting drugs and, in some patients, specially grown immune cells. The goal is to see if this approach is safe and can shrink tumors in 16 adults with advanced bone or soft tissue sarcoma who have not responded to standard treatments. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized tumor neoantigen vaccine (SarcVac) with or without tumor-specific lymphocytes and an anti-PD-1 antibody
What this could lead to: If successful, this could point toward a new treatment option for advanced sarcoma patients who have run out of standard therapies.
What could go wrong: This is a very early phase 1 trial with only 16 participants, so it is primarily testing safety. The vaccine may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA SOFT TISSUE SARCOMA (STS)

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.